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Chronic liver injury and inflammation lead to hepatic fibrosis, cirrhosis, and liver failure. Embryonic and
mesenchymal stem cells have been shown to reduce experimental liver fibrosis but have potential limitations,
including the formation of dysplastic precursors, tumors, and profibrogenic cells. Other stem-like cells may
reduce hepatic inflammation and fibrosis without tumor and profibrogenic cell formation. To test this hypoth-
esis we transplanted human amnion epithelial cells (hAEC), isolated from term delivered placenta, into
immunocompetent C57/BL6 mice at week 2 of a 4-week regimen of carbon tetrachloride (CCl4) exposure
to induce liver fibrosis. Two weeks following hAEC infusion, intact cells expressing the human-specific
markers inner mitochondrial membrane protein and human leukocyte antigen-G were found in mouse liver
without evidence of host rejection of the transplanted cells. Human albumin, known to be produced by
hAEC, was detected in sera of hAEC-treated mice. Human DNA was detected in mouse liver and also
spleen, lungs, and heart of some animals. Following hAEC transplantation, CCl4-treated animals showed
decreased serum ALT levels and reduced hepatocyte apoptosis, compared to controls. hAEC-treated mouse
liver had lower TNF-α and IL-6 protein levels and higher IL-10 compared to animals given CCl4 alone.
Compared to CCl4 controls, hAEC-treated mice showed fewer activated collagen-producing hepatic stellate
cells and less fibrosis area and collagen content. Reduced hepatic TGF-β levels in conjunction with a twofold
increase in the active form of the collagen-degrading enzyme matrix metalloproteinase-2 in hAEC-treated
mice compared to CCl4 controls may account for the reduction in fibrosis. hAEC transplantation into immu-
nocompetent mice leads to cell engraftment, reduced hepatocyte apoptosis, and decreased hepatic inflamma-
tion and fibrosis.
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INTRODUCTION the procedure costly, and life-long immune suppression
is required.
Strategies to reduce hepatic fibrosis and avoid theThe liver responds to persistent inflammation from
multiple causes, including viral infection, alcohol ex- need for organ transplantation have focused on hepatic
stellate cells (HSC), the principal collagen-producingcess, and hepatic steatosis, with a wound-healing, fibro-
genic response that in some patients can lead to cirrho- cell in the liver. Many antifibrotic therapies have been
explored but none have become available yet for clinicalsis, portal hypertension, hepatocellular carcinoma, and
liver failure. These serious disorders are associated with use (35). Recent reports have shown that transplantation
of embryonic stem cells (ESC) and adult hematopoieticsignificant mortality risk and impose considerable finan-
cial burdens on health care systems worldwide. Liver and mesenchymal stem cells (MSC) into animals with
experimental liver injury can result in transdifferentia-transplantation is the only curative therapy for end-stage
disease, but access to sufficient donors is problematic, tion of these cells into hepatocytes and in reduced fibro-
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sis (4,10,11,21,29,32), although not all authors have woman. The study was approved by the Southern Health
Human Research Ethics Committee.demonstrated positive results (8). Adverse outcomes,
such as tumor formation by ESC-derived hepatocytes (4)
Animalsand fusion of MSC with host cells to form dysplastic
precursors, have been observed (37). In addition, there Six-week-old male C57/BL6 mice were purchased
from Monash Animal Services, Melbourne, Australia.is considerable evidence that bone marrow is a source
of profibrogenic cells in the liver and that bone marrow- The study was approved by the Animal Ethics Commit-
tee, Monash University. Animals received humane carederived MSC transdifferentiate into cells capable of sup-
porting hepatic fibrogenesis (13). under the Australian code of practice for the care and
use of animals for scientific purposes.Alternatively, there are stem-like cells that may over-
come the disadvantages of ESC and MSC. We and oth-
Cell Isolationers have shown that human amnion epithelial cells
(hAEC) display features of pluripotent/multipotent stem hAEC were isolated from amnion membranes and
their purity assessed as described previously (14).cells and can transdifferentiate into several lineages de-
rived from each of the primary germ layers, including Briefly, the tissue was digested twice in 0.25% trypsin/
EDTA solution (Gibco, Grand Island, NY) for 20 minhepatocytes (14,20). The cells are plentiful; in excess of
100 million hAEC can be obtained noninvasively from with agitation at 37°C. Trypsin was inactivated with fe-
tal calf serum (Invitrogen, Carlsbad, CA) and dispersedthe amnion membrane of term delivered placenta, a
hugely abundant and noncontentious source of stem cells washed in DMEM-F12 medium (Gibco). Batches
>99% positive for the epithelial markers cytokeratin-7,cells for potential cellular therapies. Interestingly, pri-
mary undifferentiated hAEC produce a number of hepa- 8/18 (Dako, Glostrup, Denmark) by flow cytometry (14)
were used in the experiments described below.tocyte specific proteins, including serum albumin
(24,30), and can engraft in the murine liver as demon-
Induction of Hepatic Fibrosis and Cell Transplantationstrated in a study exploring the use of hAEC as a trans-
gene carrier for the treatment of inherited liver diseases Mice were given intraperitoneal injections with CCl4
(1 µl/g body weight diluted 1:10 in olive oil) twice(27).
Importantly, unlike ESC, hAEC do not form terato- weekly for 4 weeks. CCl4 administration induces ne-
croinflammatory liver injury that reproducibly causesmas or tumors following xenotransplantation (14,20).
These cells have also been successfully transplanted into hepatic fibrosis. Midway through the CCl4 treatment, an-
imals received hAEC (2 × 106 in 250 µl saline) via theallogeneic recipients because they appear to lack key
allo-recognition molecules that would elicit host im- tail vein. Previous dose–response experiments using
1–4 × 106 cells showed that 2 × 106 was the optimal cellmune responses (15). Further, anti-inflammatory proper-
ties have been attributed to hAEC and amnion mem- dose for infusion (data not shown). Control groups con-
sisted of mice given CCl4 only, CCl4 + saline (vehiclebrane and employed clinically as topical therapy in
ophthalmic and dermal applications to promote wound control), and healthy mice that did not undergo any
treatment. Each cohort consisted of 8–10 mice. Animalshealing and reduce scarring (31). A recent study investi-
gating the effects of a mixed cell population consisting were culled 4 weeks after commencing the experiment
and blood and liver tissue collected. Spleen, heart, andof hAEC and amnion-derived MSC reported a reduction
in fibrosis in lungs of bleomycin-injured mice (6). How- lungs were also collected from mice given hAEC.
ever, whether the anti-inflammatory properties of hAEC
Detection of Human Cells by DNA PCRcan be exploited following cell transplantation to reduce
fibrosis remains largely unknown. In the present study, To determine if hAEC were present in murine organs,
DNA was extracted from liver, lung, spleen, and heartwe transplanted hAEC into immune competent C57/BL6
mice with carbon tetrachloride (CCl4)-induced hepatic tissue using phenol chloroform and amplified by PCR
using primers specific for human Alu repeat sequencesfibrosis and show that hAEC xenografts survive, con-
tinue to secrete albumin, and reduce hepatic inflamma- (9). DNA extracted from healthy mouse liver served as
a control.tion and fibrosis.
MATERIALS AND METHODS Detection of Human Serum Albumin
Human Amnion Tissue Albumin secreted by primary, undifferentiated hAEC
has been measured in sera of SCID mice harboring am-Amnion membranes were obtained from healthy
women with a normal singleton pregnancy undergoing nion tissue transplants (27). As an indirect measure of
hAEC survival and functionality, sera collected fromcesarean section at term (37–40 weeks gestation; n =
16). Informed written consent was obtained from each C57/BL6 mice (hAEC treated and controls; n = 10/
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group) were tested for human serum albumin using an overnight at 4°C with 1:100 diluted caspase-3 antibody
(Promega, Madison, WI). After several washes sectionsELISA specific for the human protein (Bethyl Labora-
tories, Montgomery, TX), following the manufacturer’s were incubated sequentially with biotinylated goat anti-
mouse secondary antibodies, ABC kit reagents (Vectorinstructions.
Laboratories Burlinghame, CA); antibody binding was
Measurement of Alanine Aminotransferase (ALT) detected with DAB.
and Total Bilirubin To localize α-smooth muscle actin (α-SMA), present
in activated HSC, liver tissue sections were placed inSerum ALT and bilirubin were measured by Southern
Cross Pathology, Monash Medical Centre using reagents an autostainer (Dako) and incubated sequentially with:
peroxidase block (Dako), CAS protein block (Zymed,and calibrators from Beckmann-Coulter (Sydney, Aus-
tralia). San Francisco, CA), 1:5000 diluted α-SMA antibody
(Sigma-Aldrich), 1:300 diluted rabbit anti-mouse IgG2a
Hepatic Cytokine Concentrations (Invitrogen), ABC reagents (Vector Laboratories), and
DAB (Dako). Incubations were carried out at room tem-Liver tissue was homogenized in 50 mM Tris-HCl,
150 mM NaCl, 1% Triton X-100, 0.5% Tween-20, 0.1% perature for 15 min except primary antibody (30 min)
and DAB (5 min). Slides were counterstained with he-SDS, 1 mM EDTA, and protease inhibitor cocktail
(Roche), sonicated, and centrifuged at 14,000 × g for 15 matoxylin, dehydrated, and mounted in DPX.
min to remove debris. Interleukin (IL)-6, IL-10, tumor
Picro Sirius Red Stainingnecrosis factor-α (TNF-α), and monocyte chemoattrac-
tant protein (MCP)-1 were measured by the Cytometric Deparaffinized liver tissue sections were stained with
Picro Sirius Red to identify the extent of histological fi-Bead Array (BD Biosciences, San Jose, CA) and IL-1
and transforming growth factor-β (TGF-β) by ELISA brosis. Sections were incubated for 90 min in Picro Sirius
Red stain, washed in acetic acid and water (5:1000), de-(R&D Systems, Minneapolis, MN). Total protein con-
tent in tissue lysates was determined by the BCA assay hydrated in ethanol, and mounted in DPX. Fibrosis area
was measured by computer-assisted morphometry. Fifteen(Thermo Scientific, Rockford, IL) and cytokine concen-
trations normalized against the total protein content. consecutive nonoverlapping fields were acquired from
each mouse liver; the images were digitized and fibrosis
Immunohistochemistry area analyzed by Scion Image for Windows (vAlpha
4.0.3.2, Scion Corporation, Frederick, MD).hAEC present in the liver were identified using hu-
man inner mitochondrial membrane (IMM) protein and
Hydroxyproline Assayhuman leukocyte antigen (HLA)-G. For IMM, 4% para-
formaldehyde-fixed paraffin-embedded liver tissue sec- Hepatic collagen content was measured by the hy-
droxyproline assay, as described previously (25), withtions 5 µm in thickness were dewaxed, rehydrated, and
antigen retrieval carried out by boiling the sections in minor modifications. Briefly, liver tissue was hydro-
lyzed in 6N HCl and absorbance measured at 558 nm.citrate buffer. Endogenous peroxidase activity was
quenched in 0.6% H2O2 for 15 min. HLA-G immunohis- The hydroxyproline content was calculated from a stan-
dard curve prepared with trans-4-hydroxy-L-prolinetochemistry was performed on OCT-embedded frozen
liver tissue sections, 4 µm in thickness, fixed in 2% (Sigma-Aldrich), data were multiplied by a factor of 6.94
to convert the hydroxyproline measurement to collagenparaformaldehyde for 10 min. Protein block (Dako,
Glostrup, Denmark) was applied for 15 min followed by content and expressed per milligram of wet tissue weight.
IMM (1:100, Chemicon, Boronia, Australia) or HLA-G
Gelatin Zymographyantibodies (1:50, BD Biosciences) and incubated at
37°C for 1 h. Human term fetal membranes served as a Matrix metalloproteinases (MMPs) were extracted
from mouse liver tissue (n = 4/group). MMP-2 andpositive control. Isotype-matched mouse IgG was ap-
plied to sections serving as negative controls. Sections MMP-9 activity was assessed by gelatin zymography as
described previously (36). Densitometry of the activewere then incubated with biotinylated goat anti-mouse
secondary antibodies followed by Envision kit reagents MMP bands was performed using a GS-710 Calibrated
Imaging Densitometer (Bio-Rad, Hercules, CA) and(Dako). Antibody binding was detected using DAB
chromogen (Sigma-Aldrich, St. Louis, MO). Quantity-One software (Bio-Rad).
To identify apoptotic hepatocytes, caspase-3 staining
Statistical Analysiswas carried out. Paraffin-embedded liver tissue sections
were dewaxed, rehydrated, and antigens retrieved by Data were expressed as mean ± SEM. Statistical sig-
nificance of planned comparisons was determined byboiling in citrate buffer. Following incubation in 0.6%
H2O2 and protein block solution, sections were incubated one-way ANOVA with the Newman-Keuls post test for
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multiple comparisons (GraphPad Prism 5.0b for Mac OS Hepatocyte Apoptosis Is Reduced With
hAEC TransplantationX, GraphPad Software, San Diego, CA). Values of p <
0.05 were considered statistically significant. Engulfment of apoptotic hepatocytes by Kupffer cells
and HSC augments hepatic inflammation and fibrosis soRESULTS
we asked whether reduced hepatocyte apoptosis could
hAEC Engraft in CCl4-Injured Liver contribute to the reduction in inflammatory indices such
We and others have shown that hAEC express pluri- as serum ALT, an outcome demonstrated in other forms
potent and some mesenchymal stem cell markers includ- of experimental liver injury (18). Caspase-3-positive
ing Oct-4, Sox-2, Nanog, SSEA-4, Tra-1-60, Tra-1-80, cells were significantly more frequent in CCl4-treated
GCTM2, CD29, CD73, and CD166, have low levels of mice compared to healthy animals (p < 0.001) (Fig. 3A.
HLA class IA antigens, high levels of the class IB anti- Mice given CCl4 + hAEC showed significantly fewer
gen HLA-G, and lack HLA class II molecules. hAEC apoptotic hepatocytes (p < 0.05). Staining of serial sec-
are negative for the hematopoietic lineage markers tions showed the presence of IMM-positive hAEC in
CD31, CD34, and monocytic marker CD45 (14,20, these regions (Fig. 3B). We also investigated whether
24,26). These cells were injected intravenously into im- hAEC transplantation induced hepatocyte proliferation.
mune competent C57/BL6 mice 2 weeks after exposure While PCNA-positive cells were present throughout he-
to CCl4 and culled 2 weeks later. Intact IMM and HLA- patic lobules and portal tracts, significant differences
G-positive cells were detected in liver sections from 8 were absent among treatment groups (data not shown).
of 10 mice tested and were observed around portal tracts
hAEC Decrease Hepatic Inflammationand spreading into surrounding hepatic lobules (Fig.
1A). Due to limitations in IMM antibody binding to par- Given the reduction in hepatocyte apoptosis, we then
affin sections and HLA-G to frozen sections, colocaliza- asked whether there might also be hAEC-associated
tion using serial sections could not be carried out. hAEC changes in pro- and anti-inflammatory cytokines. Liver
lining amnion of term fetal membranes were positive tissue lysates from healthy mice and animals given CCl4
for IMM and HLA-G. Liver tissue sections from mice with or without hAEC were analyzed using a flow cy-
receiving CCl4 only and those incubated with mouse IgG tometry-based assay or ELISA. Mice transplanted with
lacked IMM and HLA-G staining. hAEC had significantly reduced IL-6 and TNF-α and
DNA PCR for human Alu repeat sequences was car- increased IL-10 hepatic protein content compared with
ried out to detect human cells in liver of CCl4-treated mice given CCl4 alone (p < 0.01, p < 0.0001, and p <
mice. Human DNA was detected in mouse liver of 4 of 0.01, respectively) (Fig. 4). IL-1 and MCP-1 protein lev-
5 hAEC-treated animals. In order to determine if hAEC els did not alter with hAEC treatment.
had engrafted in other organs, spleen, heart, and lung
hAEC Reduce HSC Activationtissues were also examined. Human DNA was detected
Activated HSC and Kupffer cells release inflamma-in spleen and lungs of 3 of 5 mice and heart tissue of
tory cytokines including TNF-α and IL-6. Because1of 5 mice tested.
hAEC transplantation led to a reduction in TNF-α andAs an indirect measure of the presence and function-
IL-6, we investigated whether HSC activation was simi-ality of hAEC, we also tested for human albumin 2
larly reduced. As expected, the number of α-SMA-posi-weeks post-cell transplantation. Human albumin was de-
tive cells was significantly elevated in CCl4-treated micetected in murine sera from all CCl4 + hAEC-treated ani-
compared with healthy controls (p < 0.001) (Fig. 5).mals and was absent in sera of mice treated with CCl4
CCl4-treated mice given hAEC demonstrated signifi-or saline vehicle, confirming the specificity of the
cantly fewer α-SMA-positive cells compared with CCl4ELISA (Fig. 1B).
alone (p < 0.001). Using serial sections, IMM-positive
hAEC Transplantation Reduces Serum ALT hAEC were found in close proximity to residual α-
Elevations in bilirubin and ALT generally reflect he- SMA-stained cells (Fig. 5B).
patocyte injury and these proteins increased significantly
hAEC Reduce Hepatic Fibrosis Areain animals given CCl4 compared to healthy controls
and TGF-β Content(p < 0.05 and p < 0.001, respectively) (Fig. 2). Serum
ALT was significantly lower in mice injected with Because HSC are the principal collagen-producing
cells in the liver, we next examined whether reducedhAEC compared to CCl4 alone (p < 0.01). Although se-
rum bilirubin was lower in mice receiving hAEC com- HSC activation was associated with reduced hepatic fi-
brosis demonstrated by Sirius red staining and quantita-pared to CCl4 alone, this reduction was not statistically
significant. tion by computer-assisted morphometry. After 4 weeks
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Figure 1. hAEC engraft in the injured liver. Cells positive for human specific IMM and HLA-G (arrows) were found in portal
triads and adjacent parenchyma. HLA-G and IMM staining of hAEC lining human fetal membranes is also shown. Sections from
mice given CCl4 only and those incubated with isotype-matched IgG lacked staining. Scale bars: 50 µm (A). Murine sera collected
2 weeks after hAEC transplantation contained human albumin providing further evidence of hAEC engraftment and survival (B).
of CCl4 treatment, fibrotic bands were clearly evident by cantly lower hepatic collagen content compared with
CCl4 alone (p < 0.05).Sirius red staining and fibrosis area was significantly
increased in CCl4-treated animals compared to untreated To explore mechanisms that could lead to a reduction
in HSC activation, we measured the profibrotic cytokinecontrols (p < 0.001) (Fig. 6A). However, mice given
hAEC showed significantly less fibrosis area compared TGF-β in hepatic tissue lysates by ELISA normalized by
protein content. TGF-β content increased significantly inwith CCl4 alone (p < 0.001). IMM-positive cells were
found adjacent to some of the fibrotic bands that were response to CCl4 compared to normal controls (p <
0.001) but was significantly lower in mice treated withstill evident in hAEC-treated mice (Fig. 6B).
We also assessed whether the histological changes CCl4 + hAEC (p < 0.01) (Fig. 7B). We also measured
changes in enzymes that alter extracellular matrix com-seen in fibrosis area were reflected in the hepatic colla-
gen content. Hepatic collagen concentration, measured position by degrading collagen. Active MMP-2 in-
creased twofold in mice treated with hAEC compared toby the hydroxyproline assay, was significantly elevated
in CCl4-treated mice compared to healthy controls (p < mice given CCl4 alone (p < 0.05) (Fig. 7C). Active
MMP-9, however, was not significantly altered with0.001) (Fig. 7). hAEC-treated animals showed signifi-
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Figure 2. hAEC transplantation reduces liver injury. Alanine aminotransferase (ALT) and total bilirubin were measured in sera of
C57/BL6 mice given cells or saline plus CCl4, healthy mice, and those given CCl4 alone. Bilirubin and ALT were elevated in CCl4-
treated animals compared to normal mice (*p < 0.05 and ***p < 0.001, respectively). Mice transplanted with hAEC had reduced
serum ALT compared those given CCl4 alone (**p < 0.01).
Figure 3. Hepatocyte apoptosis is reduced with hAEC transplantation. Caspase-3 immunohistochemistry in liver tissue sections
shows increased numbers of immunopositive nuclei in CCl4-treated animals. The number of apoptotic hepatocytes declined signifi-
cantly in mice treated with hAEC (*p < 0.05; A). Serial sections showed that areas with IMM-positive hAEC had few apoptotic
hepatocytes (B). Scale bars: 50 µm.
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Figure 4. Hepatic cytokine levels are altered with hAEC transplantation. Cytokine concentrations in hepatic tissue lysates were
determined through a multiplex bead array or ELISA (IL-1). Compared to mice exposed to CCl4, IL-6 and TNF-α were lower in
animals treated with CCl4 + hAEC (*p < 0.01, **p < 0.0001). IL-10 increased in livers of hAEC-treated mice (*p < 0.01). MCP-1
and IL-1 remained unaltered.
hAEC treatment, compared to that measured in the CCl4 tokeratin-19 immunohistochemistry to identify the hu-
man cells (6). Although factors regulating the migrationgroup alone (Fig. 7C).
and engraftment of the transplanted hAEC remain un-
DISCUSSION known, chemokines, adhesion molecules, and liver-
specific factors such as sphingosine 1-phosphate mayIn this study we have shown that hAEC engraft in
livers of immunocompetent mice and reduce CCl4- play a role (19).
We did not observe any histological evidence of hostinduced hepatic fibrosis. hAEC engraftment was demon-
strated by the presence of intact human IMM and HLA- rejection of transplanted hAEC, which were present in
portal tracts and adjacent parenchyma without the neutro-G-positive cells 2 weeks posttransplantation while the
presence of human albumin, a protein known to be se- phil or lymphocyte infiltration typical of immune-medi-
ated rejection. Similar observations have been made fol-creted by the transplanted cells (24,30), in mouse serum
suggests that the hAEC remain viable. Analysis for hu- lowing transplantation of hAEC into bonnet monkeys
with spinal cord injury (28). This may be due to factorsman DNA in several murine organs showed that the in-
travenously transplanted hAEC traffic primarily to the such as low levels of expression of HLA class IA and II
molecules and costimulatory molecules (3,14) or activeinjured liver. Consistent with these findings, Bailo et al.
reported the presence of human DNA in swine and ro- inhibition of host T-cell proliferation (2,34). hAEC are
known to express HLA-G, which serves not only as adent organs several weeks after the transplantation of
hAEC together with human amnion MSC (2). These marker to follow the fate of the transplanted cells but is
also likely to play an important role in subverting thecells were also found in lungs of bleomycin-injured C57/
BL6 mice, 2 weeks post-cell transplantation through cy- host immune response to these cells. HLA-G is a non-
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Figure 5. Hepatic stellate cell activation declines with hAEC transplantation. α-Smooth muscle actin (α-SMA) immunohistochemis-
try was performed on liver tissue sections and the number of immunopositive cells showed that activated HSC declined in mice
injected with CCl4 + hAEC compared to CCl4 alone (*p < 0.001; A). Serial sections showed IMM-positive hAEC in close proximity
to α-SMA-positive cells (B). Scale bars: 50 µm.
classical, nonpolymorphic class I molecule that was first were implicated in fibrosis reduction. However, while
engraftment of a large number of Wharton’s jelly MSCdescribed in choriocarcinoma cells (7) and is expressed
in fetal–placental cells that invade the maternal uterus and fibrosis reduction was demonstrated with this tech-
nique, the authors noted that direct hepatic injection mayand thus may modulate the maternal immune response
against the fetus (17). In addition to inhibiting prolifera- be complicated by postprocedural bleeding that could
potentially impair fibrosis reduction by inducing plate-tion of alloreactive T cells (1), HLA-G may also con-
strain host immune responses by stimulating IL-10 pro- let-derived growth factor leading to HSC activation.
The antifibrotic properties of hAEC have not beenduction by regulatory T cells (22). In this context it is
interesting to note that we found increased IL-10 protein previously investigated in experimental liver fibrosis. In
chronic liver injury, activation of HSC by TGF-β, thelevels in hepatic tissue lysates from hAEC-treated mice.
Multipotent stem cells can also be harvested from hu- prototypical fibrogenic cytokine, leads to production of
collagen and other extracellular matrix components. Weman umbilical cord. Recently, human umbilical cord
MSC (hUMSC) have been shown to decrease CCl4- found that hAEC infusion in CCl4-treated immunocom-
petent mice was associated with a significant decreaseinduced hepatic fibrosis in rodent models. Jung et al.
(16) derived hUMSC from cord blood samples and in hepatic TGF-β content with fewer α-SMA-positive
cells, suggesting decreased HSC activation. In addition,showed a decrease in markers of hepatic fibrogenesis
that was most prominent 4 weeks following tail vein CCl4-treated mice showed less histological fibrosis and
lower hepatic collagen content following hAEC infusioninfusion. Tsai et al. (33) injected hUMSC obtained from
Wharton’s jelly directly into the liver and showed de- compared to controls given CCl4 alone. The develop-
ment of this fibrolytic phenotype may occur through re-creased hepatic collagen and TGF-β content in treated
rats almost to control levels. Reduced hepatic inflamma- duction of proinflammatory signals that activate HSC
and through the increased activity of collagen degradingtion and release of bioactive factors and cytokines in
association with Wharton’s jelly cell transplantation enzymes following hAEC transplantation.
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CCl4-treated mice infused with hAEC showed lower nificantly fewer apoptotic hepatocytes than animals
given CCl4 alone. Thus, inhibition of hepatocyte apopto-hepatic tissue levels of the proinflammatory cytokines
IL-6 and TNF-α with increased expression of the anti- sis, which is a potent stimulus for hepatic fibrogenesis,
may be an additional mechanism leading to hAEC-inflammatory cytokine IL-10. This antifibrotic cytokine
profile may reflect a direct interaction between hAEC induced fibrosis reduction.
Increased expression of collagen-degrading enzymesand HSC in which hAEC-derived factors regulate HSC
activation. In support of this hypothesis, a recent study such as matrix metalloproteinases is thought to be an
important mechanism underlying fibrosis regressionshowed that IL-6 expression by cultured HSC induced
MSC secretion of IL-10 leading to decreased HSC colla- (12). Our finding that hAEC infusion was associated
with a twofold increase in MMP-2 activity compared togen production (23). Alternatively, hAEC may alter pro-
fibrogenic activation signals for Kupffer cells and HSC that seen in mice treated with CCl4 alone supports the
development of a hAEC-associated fibrolytic state andby reducing hepatocyte apoptosis. In the process of re-
moving damaged cells, engulfment of apoptotic hepato- is consistent with increased MMP-2 activity identified
by others during fibrosis regression in CCl4-treated ratscytes by Kupffer cells and HSC leads to their activation
with increased TGF-β expression, TNF-α secretion, and (39). The cellular source of MMP-2 during fibrosis re-
gression is unclear because HSC secrete MMP-2 yetdeath-receptor expression (5) and can lead to liver fibro-
sis (38). Prevention of hepatocyte apoptosis by inhibit- HSC apoptosis is an important mechanism of fibrosis
resolution (39), and we identified a significant decreaseing death-receptor-mediated pathways can prevent ex-
perimental liver fibrosis (40). In this context, we found in activated HSC following hAEC transfusion. In our
study, MMP-2 expression was significantly greater inthat CCl4-treated mice infused with hAEC showed sig-
Figure 6. hAEC transplantation reduces hepatic fibrosis. Fibrosis in liver tissue sections taken from C57/BL6 mice was visualized
by Sirius red dye staining and fibrosis area quantified by computer morphometry. Animals treated with hAEC had reduced fibrosis
area (*p < 0.001; A). Staining of serial sections showed IMM-positive hAEC closely associated with Sirius red staining in mice
treated with cells (B). Scale bars: 50 µm.
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Figure 7. hAEC treatment reduces hepatic collagen content and TGF-β levels and increases gelatinase activity. Hepatic collagen
content was measured by the hydroxyproline assay and TGF-β by ELISA (A, B). Collagen and TGF-β content were lower in CCl4-
treated mice transplanted with hAEC compared to CCl4 alone. Densitometric analysis of gelatin zymograms showed that active
MMP-2 increased in mice given hAEC compared with CCl4-treated mice (C). (*p < 0.05, **p < 0.01).
#606473 to U.M. and W.S. C.S.S. is supported by a NationalhAEC-treated animals than controls, suggesting a spe-
Heart Foundation of Australia/NHMRC RD Wright Fellow-cific effect of this cell population, although whether as
ship (#454636). E.D.W. is supported by a NHMRC Biomedical
the primary source or through interaction with other res- Career Development Award (#519539).
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